Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Remifentanil: when and how to use it

F Servin1

  • 1Département d'anesthésia, Hôpital Bichat, Paris, France.

European Journal of Anaesthesiology. Supplement
|May 1, 1997
PubMed
Summary

Remifentanil, a potent opioid, offers rapid metabolism and predictable effects, unaffected by organ dysfunction. Its unique profile necessitates changes in postoperative pain management strategies for enhanced patient safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the clinical or pharmaco-economical benefit of target controlled desflurane delivery in surgical patients using the Zeus anaesthesia machine.

Anaesthesia·2009
Same author

Evaluation of the predictive performance of four pharmacokinetic models for propofol.

British journal of anaesthesia·2009
Same author

Light or deep general anaesthesia: does it matter and how to assess it?

European journal of anaesthesiology·2008
Same author

Propofol sedation using Diprifusor target-controlled infusion in adult intensive care unit patients.

Anaesthesia·2004
Same author

Desflurane-remifentanil-nitrous oxide anaesthesia for abdominal surgery: optimal concentrations and recovery features.

Acta anaesthesiologica Scandinavica·2004
Same author

[Target controlled infusion (TCI) anesthesia using propofol. Assessment of training and practice in the operating room].

Annales francaises d'anesthesie et de reanimation·2001

Area of Science:

  • Anesthesiology and Pharmacology

Background:

  • Remifentanil is a potent mu-opioid agonist with rapid metabolism by tissue esterases.
  • This unique pharmacokinetic profile is independent of renal or hepatic function.

Purpose of the Study:

  • To evaluate the implications of remifentanil's pharmacokinetic profile on its use in general anesthesia and cardiac surgery.
  • To discuss modifications needed for postoperative pain control and sedation.

Main Methods:

  • Pharmacokinetic analysis of remifentanil metabolism.
  • Review of clinical applications in general anesthesia and cardiac surgery.
  • Assessment of impact on emergence times and postoperative pain management.

Main Results:

  • Remifentanil pharmacokinetics are unaffected by severe renal or hepatic dysfunction.
  • Dosage adjustments are not required during general anesthesia, with no undue lengthening of emergence times.
  • Rapid offset of action requires revised approaches to early postoperative pain control.

Conclusions:

  • Remifentanil can be used safely in various surgical settings, including cardiac surgery, due to predictable pharmacokinetics.
  • Its use as a sedative or postoperative analgesic requires careful administration, avoiding bolus doses.
  • Implementation of remifentanil necessitates significant changes in prescribing habits to maximize patient safety and optimize outcomes.

Related Experiment Videos